/CLDI
CLDI Stock - Calidi Biotherapeutics, Inc.
Healthcare|BiotechnologyAMEX
$1.36+3.82%
+$0.05 (+3.82%) • Dec 19
61
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.3
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.77
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+304.4%upside
Target: $5.50
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for CLDI
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$1.35 – $1.37
TARGET (TP)$5.50
STOP LOSS$1.25
RISK/REWARD1:37.6
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.08
52W High$19.20
52W Low$1.10
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | $45,000 | $449,000 | N/A |
| Gross Profit | N/A | $-1,256,000 | $-229,000 | $355,000 | N/A |
| Gross Margin | N/A | N/A | -508.9% | 79.1% | N/A |
| Operating Income | $-21,776,000 | $-28,992,000 | $-23,128,000 | $-10,482,000 | $-6,773,000 |
| Net Income | $-22,143,000 | $-29,216,000 | $-25,427,000 | $-10,933,000 | $-7,937,000 |
| Net Margin | N/A | N/A | -56504.4% | -2435.0% | N/A |
| EPS | $-35.70 | $-207.61 | $-358.80 | $14.16 | $-2.64 |
Company Overview
Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing immunotherapies for the treatment of cancer. It engages in advancing a potent allogeneic stem cell capable of carrying an anti-tumor payload for use in multiple oncology indications, including high-grade gliomas and solid tumors. The company's cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Its pipeline of products candidates in the clinic includes NeuroNova that are allogeneic neural stem cells loaded with an oncolytic adenovirus for the treatment of high-grade gliomas; and SuperNova, which are allogeneic adipose-derived mesenchymal stem cells loaded with tumor-selective CAL1 oncolytic vaccinia virus for the treatment of advanced metastatic solid tumors. The company was founded in 2014 and is based in San Diego, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
2
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
2 Bullish0 Neutral/Bearish
Price Targets
$10
Average Target
↑ 635.3% Upside
Now
$9
Low
$10
Average
$11
High
Based on 2 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 22nd 2023 | H.C. Wainwright | Initiation | Buy | $11 |
| October 9th 2023 | Robert W. Baird | Initiation | Outperform | $9 |
Earnings History & Surprises
CLDIBeat Rate
13%
Last 8 quarters
Avg Surprise
-428.6%
EPS vs Estimate
Beats / Misses
1/7
Last 12 quarters
Latest EPS
$-2.21
Q4 2025
EPS Surprise History
Q1 24
-140.0%
$-0.48vs$-0.20
Q3 24
No data
Q3 24
-1075.5%
$-16.81vs$-1.43
Q4 24
-817.6%
$-7.80vs$-0.85
Q2 25
-37.8%
$-0.51vs$-0.37
Q2 25
-1340.0%
$-2.16vs$-0.15
Q3 25
-3.6%
$-1.99vs$-1.92
Q4 25
-31.5%
$-2.21vs$-1.68
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 30, 2026 | — | — | — | — |
Q4 2025 | Nov 13, 2025 | $-1.68 | $-2.21 | -31.5% | ✗ MISS |
Q3 2025 | Aug 8, 2025 | $-1.92 | $-1.99 | -3.6% | ✗ MISS |
Q2 2025 | May 14, 2025 | $-0.15 | $-2.16 | -1340.0% | ✗ MISS |
Q2 2025 | Apr 4, 2025 | $-0.37 | $-0.51 | -37.8% | ✗ MISS |
Q4 2024 | Nov 12, 2024 | $-0.85 | $-7.80 | -817.6% | ✗ MISS |
Q3 2024 | Aug 13, 2024 | $-1.43 | $-16.81 | -1075.5% | ✗ MISS |
Q3 2024 | Aug 13, 2024 | — | $-24.48 | — | — |
Q1 2024 | Mar 19, 2024 | $-0.20 | $-0.48 | -140.0% | ✗ MISS |
Q4 2023 | Nov 14, 2023 | $-0.17 | $-0.14 | +17.6% | ✓ BEAT |
Q2 2023 | Jun 29, 2023 | — | $-152.47 | — | — |
Q1 2023 | Mar 31, 2023 | — | $-78.82 | — | — |
Q4 2022 | Dec 31, 2022 | — | $-94.60 | — | — |
Q3 2022 | Sep 29, 2022 | — | $-24.35 | — | — |
Q2 2022 | Jun 29, 2022 | — | $17.44 | — | — |
Q1 2022 | Mar 30, 2022 | — | $6.13 | — | — |
Q4 2021 | Dec 30, 2021 | — | $-14.62 | — | — |
Q3 2021 | Sep 29, 2021 | — | $-3.45 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-0.04 | — | — |
Latest News
Calidi Biotherapeutics Q3 EPS $(2.21) Misses $(1.68) Estimate
📉 NegativeBenzinga•Nov 13, 2025, 09:22 PM
Calidi Biotherapeutics Presents Data On Its First Therapeutic Candidate From Its Redtail Platform CLD-401
➖ NeutralBenzinga•Nov 10, 2025, 01:12 PM
Matica Biotechnology To Provide Analytical Development, Process Development And GMP Manufacturing To Support Calidi Biotherapeutics' Submission For CLD-401
📈 PositiveBenzinga•Nov 3, 2025, 01:13 PM
Calidi Biotherapeutics Sells 22.5M Nova Cell Shares For $6M; Nova Cell No Longer Subsidiary; Estimates It Will Realize $500K Per Year In General And Administrative Expense Reductions As A Result Of The Transaction
📈 PositiveBenzinga•Oct 31, 2025, 08:29 PM
Calidi Biotherapeutics Presents New Data On First Therapeutic Candidate From RedTail Platform, CLD-401, At SITC Annual Meeting
📈 PositiveBenzinga•Oct 30, 2025, 12:06 PM
Calidi Biotherapeutics Forms Scientific Advisory Board To Further Develop RedTail Platform And Advance CLD-401 Into Clinic
📈 PositiveBenzinga•Oct 22, 2025, 12:05 PM
Calidi Biotherapeutics shares are trading lower after the company announced the pricing of a $6 million underwritten public offering of 1,472,764 units at $2.00 per unit.
📉 NegativeBenzinga•Aug 20, 2025, 03:00 PM
Calidi Biotherapeutics Prices $6M Underwritten Public Offering Of 1,472,764 Units At $2.00/Unit
➖ NeutralBenzinga•Aug 20, 2025, 01:16 PM
Frequently Asked Questions about CLDI
What is CLDI's current stock price?
Calidi Biotherapeutics, Inc. (CLDI) is currently trading at $1.36 per share. The stock has moved +3.82% today.
What is the analyst price target for CLDI?
The average analyst price target for CLDI is $5.50, based on 1 analyst.
What sector is Calidi Biotherapeutics, Inc. in?
Calidi Biotherapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the AMEX exchange.
What is CLDI's market cap?
Calidi Biotherapeutics, Inc. has a market capitalization of $0.01 billion, making it a small-cap company.
Does CLDI pay dividends?
No, Calidi Biotherapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorCANF
Can-Fite BioPharma Ltd.
$0.25
Mkt Cap: $0.0B
CMND
Clearmind Medicine Inc.
$2.74
Mkt Cap: $0.0B
CNSP
CNS Pharmaceuticals, Inc.
$6.51
Mkt Cap: $0.0B
KZIA
Kazia Therapeutics Limited
$10.87
Mkt Cap: $0.0B
QLGN
Qualigen Therapeutics, Inc.
$3.21
Mkt Cap: $0.0B
SILO
Silo Pharma, Inc.
$0.38
Mkt Cap: $0.0B
SNGX
Soligenix, Inc.
$1.38
Mkt Cap: $0.0B
SXTP
60 Degrees Pharmaceuticals, Inc.
$0.76
Mkt Cap: $0.0B
TTNP
Titan Pharmaceuticals, Inc.
$2.34
Mkt Cap: $0.0B
XBIO
Xenetic Biosciences, Inc.
$2.15
Mkt Cap: $0.0B
Explore stocks similar to CLDI for comparison